FindMyKOL

Jennifer Kirby, MD

Basic profile

University of Virginia

ORCIDOn fileNPIOn fileSign in to see identifiers
RegionCharlottesville, VA · SoutheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 2022FindMyKOL typeFindMyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Jennifer Kirby is an Endocrinology/Metabolic physician affiliated with University of Virginia. OpenAlex indexes 37 publications with 778 citations (h-index 15).

Overview

Scholarship

indexed output and impact (OpenAlex)
37publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

778citations

Citations across these publications.

15h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • KVK-Tech, Inc.
    Program year20223 payments
    $14
  • KVK-Tech, Inc.
    Program year20219 payments
    $42

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    72.2%
    GLP-1 receptor agonist23.8%
    Ozempic53%Trulicity31%Mounjaro9%Victoza 3-Pak5%Rybelsus2%
    Part D<11 patients
    Insulin Analog22.3%
    Lantus Solostar24%Humalog Kwikpen U-10015%Novolog13%Novolog Flexpen12%Tresiba Flextouch U-1008%Lantus7%Humalog4%Basaglar Kwikpen U-1004%Levemir Flexpen3%Toujeo Max Solostar3%Humalog Kwikpen U-2003%Tresiba Flextouch U-2003%
    Part D<11 patients

    + 7 more classes in this area

  • Cardiovascular

    12.8%
    Statin4.9%
    Atorvastatin Calcium62%Simvastatin26%Rosuvastatin Calcium13%
    Part D<11 patients
    ACE inhibitor2.6%
    Lisinopril100%
    Part D≥19 patients

    + 4 more classes in this area

  • Hormonal (systemic)

    10.9%
    l-Thyroxine8.8%
    Levothyroxine Sodium81%Synthroid19%
    Part D≥67 patients
    Antihypoglycemic Agent0.9%
    Gvoke Hypopen 2-Pack54%Baqsimi46%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)10.7% facility · 89.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”